scispace - formally typeset
Search or ask a question
Journal ArticleDOI

RUCAM in drug and herb induced liver injury: The update

24 Dec 2015-International Journal of Molecular Sciences (Int J Mol Sci)-Vol. 17, Iss: 1, pp 14
TL;DR: The update of the well accepted original RUCAM scale is presented and its use for clinical, regulatory, publication, and expert purposes to validly establish causality in cases of suspected DILI and HILI is recommended, facilitating a straightforward application and an internationally harmonized approach of causality assessment as a common basic tool.
Abstract: RUCAM (Roussel Uclaf Causality Assessment Method) or its previous synonym CIOMS (Council for International Organizations of Medical Sciences) is a well established tool in common use to quantitatively assess causality in cases of suspected drug induced liver injury (DILI) and herb induced liver injury (HILI). Historical background and the original work confirm the use of RUCAM as single term for future cases, dismissing now the term CIOMS for reasons of simplicity and clarity. RUCAM represents a structured, standardized, validated, and hepatotoxicity specific diagnostic approach that attributes scores to individual key items, providing final quantitative gradings of causality for each suspect drug/herb in a case report. Experts from Europe and the United States had previously established in consensus meetings the first criteria of RUCAM to meet the requirements of clinicians and practitioners in care for their patients with suspected DILI and HILI. RUCAM was completed by additional criteria and validated, assisting to establish the timely diagnosis with a high degree of certainty. In many countries and for more than two decades, physicians, regulatory agencies, case report authors, and pharmaceutical companies successfully applied RUCAM for suspected DILI and HILI. Their practical experience, emerging new data on DILI and HILI characteristics, and few ambiguous questions in domains such alcohol use and exclusions of non-drug causes led to the present update of RUCAM. The aim was to reduce interobserver and intraobserver variability, to provide accurately defined, objective core elements, and to simplify the handling of the items. We now present the update of the well accepted original RUCAM scale and recommend its use for clinical, regulatory, publication, and expert purposes to validly establish causality in cases of suspected DILI and HILI, facilitating a straightforward application and an internationally harmonized approach of causality assessment as a common basic tool.
Citations
More filters
Journal ArticleDOI
TL;DR: These Clinical Practice Guidelines summarize the available evidence on risk factors, diagnosis, management and risk minimization strategies for drug-induced liver jury.

504 citations


Cites background from "RUCAM in drug and herb induced live..."

  • ...A crucial prerequisite is proper reporting of suspected DILI cases to regulatory agencies, capturing information on time to onset, clinical course, risk factors, concomitant drugs, relevant medical history, and response to re-administration.(63,374,375) Hy’s law cases should be reported to the agencies as a serious adverse event even in the postmarketing setting, and before completion of follow-up assessments....

    [...]

Journal ArticleDOI
23 Mar 2017-Gut
TL;DR: The provision of more advanced scientific and regulatory guidance for liver safety assessment will depend on validating the new diagnostic markers in the ongoing DILI registries, biobanks and public–private partnerships.
Abstract: Idiosyncratic drug-induced liver injury (IDILI) is a rare but potentially severe adverse drug reaction that should be considered in patients who develop laboratory criteria for liver injury secondary to the administration of a potentially hepatotoxic drug. Although currently used liver parameters are sensitive in detecting DILI, they are neither specific nor able to predict the patient's subsequent clinical course. Genetic risk assessment is useful mainly due to its high negative predictive value, with several human leucocyte antigen alleles being associated with DILI. New emerging biomarkers which could be useful in assessing DILI include total keratin18 (K18) and caspase-cleaved keratin18 (ccK18), macrophage colony-stimulating factor receptor 1, high mobility group box 1 and microRNA-122. From the numerous in vitro test systems that are available, monocyte-derived hepatocytes generated from patients with DILI show promise in identifying the DILI-causing agent from among a panel of coprescribed drugs. Several computer-based algorithms are available that rely on cumulative scores of known risk factors such as the administered dose or potential liabilities such as mitochondrial toxicity, inhibition of the bile salt export pump or the formation of reactive metabolites. A novel DILI cluster score is being developed which predicts DILI from multiple complimentary cluster and classification models using absorption-distribution-metabolism-elimination-related as well as physicochemical properties, diverse substructural descriptors and known structural liabilities. The provision of more advanced scientific and regulatory guidance for liver safety assessment will depend on validating the new diagnostic markers in the ongoing DILI registries, biobanks and public-private partnerships.

327 citations

Journal ArticleDOI
22 Aug 2019
TL;DR: Drug-induced liver injury (DILI) is an adverse reaction to drugs or other xenobiotics that occurs either as a predictable event when an individual is exposed to toxic doses of some compounds or as an unpredictable event with many drugs in common use as discussed by the authors.
Abstract: Drug-induced liver injury (DILI) is an adverse reaction to drugs or other xenobiotics that occurs either as a predictable event when an individual is exposed to toxic doses of some compounds or as an unpredictable event with many drugs in common use. Drugs can be harmful to the liver in susceptible individuals owing to genetic and environmental risk factors. These risk factors modify hepatic metabolism and excretion of the DILI-causative agent leading to cellular stress, cell death, activation of an adaptive immune response and a failure to adapt, with progression to overt liver injury. Idiosyncratic DILI is a relative rare hepatic disorder but can be severe and, in some cases, fatal, presenting with a variety of phenotypes, which mimic other hepatic diseases. The diagnosis of DILI relies on the exclusion of other aetiologies of liver disease as specific biomarkers are still lacking. Clinical scales such as CIOMS/RUCAM can support the diagnostic process but need refinement. A number of clinical variables, validated in prospective cohorts, can be used to predict a more severe DILI outcome. Although no pharmacological therapy has been adequately tested in randomized clinical trials, corticosteroids can be useful, particularly in the emergent form of DILI related to immune-checkpoint inhibitors in patients with cancer.

298 citations

Journal ArticleDOI
TL;DR: The CSH guidelines summarized the epidemiology, pathogenesis, pathology, and clinical manifestation and gives 16 evidence-based recommendations on diagnosis, differential diagnosis, treatment, and prevention of DILI.
Abstract: Drug-induced liver injury (DILI) is an important clinical problem, which has received more attention in recent decades. It can be induced by small chemical molecules, biological agents, traditional Chinese medicines (TCM), natural medicines (NM), health products (HP), and dietary supplements (DS). Idiosyncratic DILI is far more common than intrinsic DILI clinically and can be classified into hepatocellular injury, cholestatic injury, hepatocellular-cholestatic mixed injury, and vascular injury based on the types of injured target cells. The CSH guidelines summarized the epidemiology, pathogenesis, pathology, and clinical manifestation and gives 16 evidence-based recommendations on diagnosis, differential diagnosis, treatment, and prevention of DILI.

185 citations

Journal ArticleDOI
TL;DR: The known signaling pathways in APAP toxicity, a model of necrotic liver cell death, are examined and what is known about the genetic basis of IDILI and the molecular pathways leading to immune activation are explored and how these events can trigger hepatotoxicity and cell death are explored.
Abstract: Drug-induced liver injury (DILI) can broadly be divided into predictable and dose dependent such as acetaminophen (APAP) and unpredictable or idiosyncratic DILI (IDILI). Liver injury from drug hepatotoxicity (whether idiosyncratic or predictable) results in hepatocyte cell death and inflammation. The cascade of events leading to DILI and the cell death subroutine (apoptosis or necrosis) of the cell depend largely on the culprit drug. Direct toxins to hepatocytes likely induce oxidative organelle stress (such as endoplasmic reticulum (ER) and mitochondrial stress) leading to necrosis or apoptosis, while cell death in idiosyncratic DILI (IDILI) is usually the result of engagement of the innate and adaptive immune system (likely apoptotic), involving death receptors (DR). Here, we review the hepatocyte cell death pathways both in direct hepatotoxicity such as in APAP DILI as well as in IDILI. We examine the known signaling pathways in APAP toxicity, a model of necrotic liver cell death. We also explore what is known about the genetic basis of IDILI and the molecular pathways leading to immune activation and how these events can trigger hepatotoxicity and cell death.

185 citations


Cites background from "RUCAM in drug and herb induced live..."

  • ...Most clinicians diagnose DILI based on previous knowledge of a drug, temporal relationship and by ruling out other causes of liver injury which is applicable to patient safety [180]....

    [...]

References
More filters
Journal ArticleDOI
TL;DR: It was shown that the ADR probability scale has consensual, content, and concurrent validity and may be applicable to postmarketing drug surveillance.
Abstract: The estimation of the probability that a drug caused an adverse clinical event is usually based on clinical judgment. Lack of a method for establishing causality generates large between-raters and within-raters variability in assessment. Using the conventional categories and definitions of definite, probable, possible, and doubtful adverse drug reactions (ADRs), the between-raters agreement of two physicians and four pharmacists who independently assessed 63 randomly selected alleged ADRs was 38% to 63%, kappa (k, a chance-corrected index of agreement) varied from 0.21 to 0.40, and the intraclass correlation coefficient of reliability (R[est]) was 0.49. Six (testing) and 22 wk (retesting) later the same observers independently reanalyzed the 63 cases by assigning a weighted score (ADR probability scale) to each of the components that must be considered in establishing causal associations between drug(s) and adverse events (e.g., temporal sequence). The cases were randomized to minimize the influence of learning. The event was assigned a probability category from the total score. The between-raters reliability (range: percent agreement = 83% to 92%; κ = 0.69 to 0.86; r = 0.91 to 0.95; R(est) = 0.92) and within-raters reliability (range: percent agreement = 80% to 97%; κ = 0.64 to 0.95; r = 0.91 to 0.98) improved (p < 0.001). The between-raters reliability was maintained on retesting (range: r = 0.84 to 0.94; R(est) = 0.87). The between-raters reliability of three attending physicians who independently assessed 28 other prospectively collected cases of alleged ADRs was very high (range: r = 0.76 to 0.87; R(est) = 0.80). It was also shown that the ADR probability scale has consensual, content, and concurrent validity. This systematic method offers a sensitive way to monitor ADRs and may be applicable to postmarketing drug surveillance. Clinical Pharmacology and Therapeutics (1981) 30, 239–245; doi:10.1038/clpt.1981.154

9,840 citations


"RUCAM in drug and herb induced live..." refers background or methods in this paper

  • ...The use of the liver unspecific Naranjo scale [56] in suspected DILI and HILI cases is problematic [4,53,60–65,76] as criteria of hepatotoxicity and reexposure conditions, specific time to onset, criteria for recovery time, and critical diagnoses to exclude are not even unconsidered (Table 6) [53]....

    [...]

  • ...[56], for the WHO from the WHO database [57], and for the ad-hoc approach from Kaplowitz [58]....

    [...]

  • ...Since these items are irrelevant for DILI and HILI, they have less sensitivity for rare and idiosyncratic reactions prevalent in liver injury [53,56]....

    [...]

  • ...Among these liver unspecific methods is the Naranjo scale [56], the WHO global introspection method, WHO method in short [57], the ad hoc approach [58], and the KL method named after Karch and Lasagna [59]....

    [...]

Journal ArticleDOI
TL;DR: A reliable diagnosis of AIH can be made using a very simple diagnostic score proposed, which is the diagnosis of probable AIH at a cutoff point greater than 6 points and definite AIH 7 points or higher.

1,415 citations


"RUCAM in drug and herb induced live..." refers methods in this paper

  • ...In this disease category belongs as examples not only the autoimmune hepatitis (AIH) that is well diagnosed by a specific score [52] and relapse while the suspected product has been discontinued, but also DILI and HILI that were validly diagnosed by the scoring causality method of the original RUCAM [8,9] and can now better be diagnosed with the updated RUCAM (Tables 2 and 3)....

    [...]

Journal ArticleDOI
TL;DR: In this paper, a new method for drug causality assessment is described and applied to reports of acute liver injuries, using reports with positive rechallenge as external standard.

1,291 citations


"RUCAM in drug and herb induced live..." refers background or methods in this paper

  • ...Summing up the points of the criteria gives an overall assessment score that reflects the likelihood that the hepatic injury is due to a specific medication [8]....

    [...]

  • ...Establishing RUCAM with all core items and specific details was time-consuming and required some years as RUCAM was the first liver-specific causality CAM for DILI ever published worldwide [8,9]....

    [...]

  • ...This was originally named RUCAM (Roussel Uclaf Causality Assessment Method) [8,9] or later also synonymously CIOMS (Council for International Organizations of Medical Sciences) [33–36]....

    [...]

  • ...Those who then applied this final scal [8,9] called it eith r RUCAM or CIOMS in their publications [33–36]....

    [...]

  • ...In the majority of the DILI and HILI cases, injury is the result of an idiosyncratic reaction at recommended doses [8,14,18]....

    [...]

Journal ArticleDOI
Bénichou C1
TL;DR: An international meeting was organized to test the feasibility of adapting for international use the outcome of the French consensus meetings on drug-induced liver disorders, and resulted in a series of proposed standard designations of drug- induced liver disorders and criteria of causality assessment.

1,055 citations


"RUCAM in drug and herb induced live..." refers background or methods in this paper

  • ...Published in 1988, the first pragmatic hepatotoxicity CAM based on the qualitative French CAM with chronological and clinical criteria was designed specifically for liver injury cases by considering some characteristic features [39] and formed a sophisticated basis for subsequent algorithms [8,9,40]....

    [...]

  • ...Preceding versions were extended, specified, and quantified, while additional criteria have been introduced and weights attributed [39,40]....

    [...]

  • ...Its previous alternative name of CIOMS (Council for International Organizations of Medical Sciences) ascribed by some authors applying RUCAM goes back to the fact that the consensus meeting in Paris in 1989 was held under the auspices of the Council for International Organizations of Medical Sciences (CIOMS), directed at establishing definitions and uniform criteria for DILI [40]....

    [...]

  • ...Its previous alternative name of CIOMS (Council for International Organizations of Medical Sciences) ascribed by some authors applying RUCAM goes back to the fact that the consensus meeting in Paris in 1989 was held under the auspices of the Council for International Organizations of Medical Sciences (CIO S), directed at establishing definitions and uniform criteri for DILI [40]....

    [...]

  • ...The respective criteria were based on the conclusions of International Consensus Meetings in 1988 [39] and 1990 [40], as reviewed previously [8,9] and recently [14,48,49]....

    [...]

Journal ArticleDOI
TL;DR: Findings provide new insights into the mechanism of flucloxacillin DILI and have the potential to substantially improve diagnosis of this serious disease.
Abstract: Drug-induced liver injury (DILI) is an important cause of serious liver disease. The antimicrobial agent flucloxacillin is a common cause of DILI, but the genetic basis for susceptibility remains unclear. We conducted a genome-wide association (GWA) study using 866,399 markers in 51 cases of flucloxacillin DILI and 282 controls matched for sex and ancestry. The GWA showed an association peak in the major histocompatibility complex (MHC) region with the strongest association (P = 8.7 x 10(-33)) seen for rs2395029[G], a marker in complete linkage disequilibrium (LD) with HLA-B*5701. Further MHC genotyping, which included 64 flucloxacillin-tolerant controls, confirmed the association with HLA-B*5701 (OR = 80.6, P = 9.0 x 10(-19)). The association was replicated in a second cohort of 23 cases. In HLA-B*5701 carrier cases, rs10937275 in ST6GAL1 on chromosome 3 also showed genome-wide significance (OR = 4.1, P = 1.4 x 10(-8)). These findings provide new insights into the mechanism of flucloxacillin DILI and have the potential to substantially improve diagnosis of this serious disease.

949 citations


"RUCAM in drug and herb induced live..." refers background or methods in this paper

  • ...RUCAM has been used to identify DILI and HILI events in case studies of prescription drugs [8,9,112,172], herbal medications [14,168], regulatory evaluations [81,86–88,90,92,94], epidemiological studies [2,99,113,173], genotyping studies [83,100], phase I clinical studies [154] and long-term post marketing clinical trials [5,102,158], just to name a few examples....

    [...]

  • ...DILI Flucloxacillin UK, other countries DILIGEN Study & International SAE Consortium 2009 Daly [83]...

    [...]

Related Papers (5)